Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line Nal-IRI + 5-FU + folinic acid after gemcitabine/nab-paclitaxel failure in advanced pancreatic cancer
2016-005147-17Phase 3Completed
- Sponsor
- AIO-Studien
- Start
- Oct 2017
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of nanoliposomal irinotecan in pancreatic cancer (PC), sponsored by AIO-Studien. Started Oct 2017; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2016-005147-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005147-17.